Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis

Tadaki Nakahara, Yaeko Takagi, Kazuhiko Takemasa, Yoko Mitsui, Akira Tsuyuki, Naoyuki Shigematsu, Atsushi Kubo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Therapeutic assessment with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is sometimes problematic after radiation therapy. Herein we describe a patient with acute radiation-induced hepatitis in which PET showed dose-dependent FDG uptake. A 50-year-old man underwent FDG PET for staging of esophageal cancer. Chemoradiotherapy was delivered concurrently with a radiation field that expanded from the esophagus into the upper stomach to cover metastasis of the gastric wall. The patient also underwent FDG PET 26 days and 4 months after chemoradiotherapy to evaluate the therapeutic effect Twenty-eight days after chemoradiotherapy, hematochemistry revealed elevated hepatic enzymes and postcontrast computed tomography showed band-like hypoattenuation in the liver with parenchymal swelling corresponding to the radiation field. FDG PET performed 26 days after chemoradiotherapy showed a wedge-shaped hypermetabolic area in which the degree of FDG uptake correlated with the prescribed radiation dose. Follow-up PET 4 months after therapy showed no abnormal uptake in the liver. Acute radiation- induced hepatitis can be a potential cause of faise-positve findings of malignancy on FDG PET scans, and PET images should carefully be compared with the distribution of prescribed dose. Threshold dose might be higher for metabolic changes than for morphologic changes.

Original languageEnglish
Pages (from-to)1040-1044
Number of pages5
JournalEuropean Journal of Gastroenterology and Hepatology
Volume20
Issue number10
DOIs
Publication statusPublished - 2008 Oct

Fingerprint

Positron-Emission Tomography
Hepatitis
Radiation
Chemoradiotherapy
Liver
Stomach
Fluorodeoxyglucose F18
Therapeutic Uses
Esophageal Neoplasms
Esophagus
Radiotherapy
Tomography
Neoplasm Metastasis
Enzymes
Therapeutics
Neoplasms

Keywords

  • Fluorodeoxyglucose
  • Positron emission tomography
  • Radiation dose
  • Radiation hepatitis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis. / Nakahara, Tadaki; Takagi, Yaeko; Takemasa, Kazuhiko; Mitsui, Yoko; Tsuyuki, Akira; Shigematsu, Naoyuki; Kubo, Atsushi.

In: European Journal of Gastroenterology and Hepatology, Vol. 20, No. 10, 10.2008, p. 1040-1044.

Research output: Contribution to journalArticle

Nakahara, Tadaki ; Takagi, Yaeko ; Takemasa, Kazuhiko ; Mitsui, Yoko ; Tsuyuki, Akira ; Shigematsu, Naoyuki ; Kubo, Atsushi. / Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis. In: European Journal of Gastroenterology and Hepatology. 2008 ; Vol. 20, No. 10. pp. 1040-1044.
@article{ec2f4c3ebea248e0966969d2267e4f48,
title = "Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis",
abstract = "Therapeutic assessment with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is sometimes problematic after radiation therapy. Herein we describe a patient with acute radiation-induced hepatitis in which PET showed dose-dependent FDG uptake. A 50-year-old man underwent FDG PET for staging of esophageal cancer. Chemoradiotherapy was delivered concurrently with a radiation field that expanded from the esophagus into the upper stomach to cover metastasis of the gastric wall. The patient also underwent FDG PET 26 days and 4 months after chemoradiotherapy to evaluate the therapeutic effect Twenty-eight days after chemoradiotherapy, hematochemistry revealed elevated hepatic enzymes and postcontrast computed tomography showed band-like hypoattenuation in the liver with parenchymal swelling corresponding to the radiation field. FDG PET performed 26 days after chemoradiotherapy showed a wedge-shaped hypermetabolic area in which the degree of FDG uptake correlated with the prescribed radiation dose. Follow-up PET 4 months after therapy showed no abnormal uptake in the liver. Acute radiation- induced hepatitis can be a potential cause of faise-positve findings of malignancy on FDG PET scans, and PET images should carefully be compared with the distribution of prescribed dose. Threshold dose might be higher for metabolic changes than for morphologic changes.",
keywords = "Fluorodeoxyglucose, Positron emission tomography, Radiation dose, Radiation hepatitis",
author = "Tadaki Nakahara and Yaeko Takagi and Kazuhiko Takemasa and Yoko Mitsui and Akira Tsuyuki and Naoyuki Shigematsu and Atsushi Kubo",
year = "2008",
month = "10",
doi = "10.1097/MEG.0b013e3282f5f5d5",
language = "English",
volume = "20",
pages = "1040--1044",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis

AU - Nakahara, Tadaki

AU - Takagi, Yaeko

AU - Takemasa, Kazuhiko

AU - Mitsui, Yoko

AU - Tsuyuki, Akira

AU - Shigematsu, Naoyuki

AU - Kubo, Atsushi

PY - 2008/10

Y1 - 2008/10

N2 - Therapeutic assessment with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is sometimes problematic after radiation therapy. Herein we describe a patient with acute radiation-induced hepatitis in which PET showed dose-dependent FDG uptake. A 50-year-old man underwent FDG PET for staging of esophageal cancer. Chemoradiotherapy was delivered concurrently with a radiation field that expanded from the esophagus into the upper stomach to cover metastasis of the gastric wall. The patient also underwent FDG PET 26 days and 4 months after chemoradiotherapy to evaluate the therapeutic effect Twenty-eight days after chemoradiotherapy, hematochemistry revealed elevated hepatic enzymes and postcontrast computed tomography showed band-like hypoattenuation in the liver with parenchymal swelling corresponding to the radiation field. FDG PET performed 26 days after chemoradiotherapy showed a wedge-shaped hypermetabolic area in which the degree of FDG uptake correlated with the prescribed radiation dose. Follow-up PET 4 months after therapy showed no abnormal uptake in the liver. Acute radiation- induced hepatitis can be a potential cause of faise-positve findings of malignancy on FDG PET scans, and PET images should carefully be compared with the distribution of prescribed dose. Threshold dose might be higher for metabolic changes than for morphologic changes.

AB - Therapeutic assessment with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is sometimes problematic after radiation therapy. Herein we describe a patient with acute radiation-induced hepatitis in which PET showed dose-dependent FDG uptake. A 50-year-old man underwent FDG PET for staging of esophageal cancer. Chemoradiotherapy was delivered concurrently with a radiation field that expanded from the esophagus into the upper stomach to cover metastasis of the gastric wall. The patient also underwent FDG PET 26 days and 4 months after chemoradiotherapy to evaluate the therapeutic effect Twenty-eight days after chemoradiotherapy, hematochemistry revealed elevated hepatic enzymes and postcontrast computed tomography showed band-like hypoattenuation in the liver with parenchymal swelling corresponding to the radiation field. FDG PET performed 26 days after chemoradiotherapy showed a wedge-shaped hypermetabolic area in which the degree of FDG uptake correlated with the prescribed radiation dose. Follow-up PET 4 months after therapy showed no abnormal uptake in the liver. Acute radiation- induced hepatitis can be a potential cause of faise-positve findings of malignancy on FDG PET scans, and PET images should carefully be compared with the distribution of prescribed dose. Threshold dose might be higher for metabolic changes than for morphologic changes.

KW - Fluorodeoxyglucose

KW - Positron emission tomography

KW - Radiation dose

KW - Radiation hepatitis

UR - http://www.scopus.com/inward/record.url?scp=53549110797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549110797&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e3282f5f5d5

DO - 10.1097/MEG.0b013e3282f5f5d5

M3 - Article

VL - 20

SP - 1040

EP - 1044

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 10

ER -